| Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease OMA El‐Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson, ... The FASEB journal 20 (3), 419-425, 2006 | 772 | 2006 |
| α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma OMA El-Agnaf, SA Salem, KE Paleologou, LJ Cooper, NJ Fullwood, ... The FASEB Journal 17 (13), 1-16, 2003 | 683 | 2003 |
| Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of α-synuclein KE Paleologou, AW Schmid, CC Rospigliosi, HY Kim, GR Lamberto, ... Journal of Biological Chemistry 283 (24), 16895-16905, 2008 | 424 | 2008 |
| Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions KE Paleologou, A Oueslati, G Shakked, CC Rospigliosi, HY Kim, ... Journal of Neuroscience 30 (9), 3184-3198, 2010 | 391 | 2010 |
| Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease OM El-Agnaf, SA Salem, KE Paleologou, MD Curran, MJ Gibson Faseb j 20 (3), 419-425, 2006 | 367 | 2006 |
| Phosphorylation of synucleins by members of the Polo-like kinase family MK Mbefo, KE Paleologou, A Boucharaba, A Oueslati, H Schell, ... Journal of Biological Chemistry 285 (4), 2807-2822, 2010 | 284 | 2010 |
| Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia BJ Tabner, OMA El-Agnaf, S Turnbull, MJ German, KE Paleologou, ... Journal of Biological Chemistry 280 (43), 35789-35792, 2005 | 284 | 2005 |
| Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies KE Paleologou, CL Kragh, DMA Mann, SA Salem, R Al-Shami, D Allsop, ... Brain 132 (4), 1093-1101, 2009 | 254 | 2009 |
| A strategy for designing inhibitors of α‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders OMA El-Agnaf, KE Paleologou, B Greer, AM Abogrein, JE King, SA Salem, ... The FASEB journal 18 (11), 1315-1317, 2004 | 223 | 2004 |
| A strategy for designing inhibitors of α‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders OMA El-Agnaf, KE Paleologou, B Greer, AM Abogrein, JE King, SA Salem, ... The FASEB journal 18 (11), 1315-1317, 2004 | 223 | 2004 |
| Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's β-amyloid peptide BM Austen, KE Paleologou, SAE Ali, MM Qureshi, D Allsop, ... Biochemistry 47 (7), 1984-1992, 2008 | 184 | 2008 |
| Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including … OM El-Agnaf, SA Salem, KE Paleologou, LJ Cooper, NJ Fullwood, ... Faseb j 17 (13), 1945-1947, 1945 | 158 | 1945 |
| Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology NN Vaikath, NK Majbour, KE Paleologou, MT Ardah, E van Dam, ... Neurobiology of disease 79, 81-99, 2015 | 148 | 2015 |
| Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α-synuclein and β-amyloid and protect against amyloid-induced toxicity S Di Giovanni, S Eleuteri, KE Paleologou, G Yin, M Zweckstetter, ... Journal of Biological Chemistry 285 (20), 14941-14954, 2010 | 148 | 2010 |
| Inhibition of α-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region FE Herrera, A Chesi, KE Paleologou, A Schmid, A Munoz, M Vendruscolo, ... PloS one 3 (10), e3394, 2008 | 141 | 2008 |
| Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity MT Ardah, KE Paleologou, G Lv, SB Abul Khair, AS Kazim, ST Minhas, ... Frontiers in aging neuroscience 6, 197, 2014 | 130 | 2014 |
| Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease A Oueslati, KE Paleologou, BL Schneider, P Aebischer, HA Lashuel Journal of Neuroscience 32 (5), 1536-1544, 2012 | 117 | 2012 |
| Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils MT Ardah, KE Paleologou, G Lv, SA Menon, SBA Khair, JH Lu, ... Neurobiology of disease 74, 89-101, 2015 | 111 | 2015 |
| α-Synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy KE Paleologou, GB Irvine, OMA El-Agnaf Biochemical Society Transactions 33 (5), 1106-1110, 2005 | 78 | 2005 |
| Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers JO Aasly, KK Johansen, G Brønstad, BJ Warø, NK Majbour, S Varghese, ... Frontiers in Aging Neuroscience 6, 248, 2014 | 70 | 2014 |
Omar El-AgnafQatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar FoundationVerified email at hbku.edu.qa
